Ever Supreme Bio Technology Co., Ltd
6712
Rank in Stocks
#12677
This enterprise is dedicated to the investigation, advancement, and creation of... This enterprise is dedicated to the investigation, advancement, and creation of pharmaceutical treatments leveraging human mesenchymal stem cells and immune cells. Its current portfolio features UMC01, a drug candidate undergoing Phase I clinical evaluation for addressing conditions such as myocardial infarction and stroke. Additionally, ADCV01 is progressing through Phase II clinical trials as a potential therapy for aggressive brain tumors. The company also develops CAR001, an innovative chimeric antigen receptor immune cell product, alongside bone-marrow stem cells (BMSC) used in managing chronic stroke, severe osteoarthritis, and spinal cord injuries. Established in 2016, the firm operates from its headquarters in Taichung, Taiwan.
Share Price
$4.47
Last synced: 2026-11-10
Market Cap
$448.78M
Change (1 day)
-1.01%
Change (1 year)
-9.16%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Ever Supreme Bio Technology Co., Ltd (6712)
Category
Healthcare
Operating Margin for Ever Supreme Bio Technology Co., Ltd (6712)
Operating Margin as of November 2026 TTM: 44.16%
According to Ever Supreme Bio Technology Co., Ltd's latest financial reports, its current operating margin (TTM) is 44.16%. At the end of 2025 the company had an operating margin of 43.14%.
Operating Margin history for Ever Supreme Bio Technology Co., Ltd from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 44.16% | 2.36% |
| 2025 | 43.14% | -4.35% |
| 2024 | 45.10% | 1.28% |
| 2023 | 44.53% | 5.60% |
| 2022 | 42.17% | -53.44% |
| 2021 | 90.57% | -146.80% |
| 2020 | -193.52% | -84.55% |
| 2019 | -1,252.31% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.13% |
US
|
|
| -149.01% | -103.37% |
US
|
|
| 25.57% | -99.42% |
AU
|
|
| 31.23% | -99.29% |
BE
|
|
| 29.35% | -99.34% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Ever Supreme Bio Technology Co., Ltd's operating margin
What is Ever Supreme Bio Technology Co., Ltd's operating margin?
Ever Supreme Bio Technology Co., Ltd's operating margin is 44.16%, as of Nov 2026.
What was Ever Supreme Bio Technology Co., Ltd's operating margin in 2025?
In 2025, Ever Supreme Bio Technology Co., Ltd's operating margin was 43.14%, compared with 45.10% in 2024.
How has Ever Supreme Bio Technology Co., Ltd's operating margin changed since 2020?
From 2020 to 2025, Ever Supreme Bio Technology Co., Ltd's operating margin was highest in 2021 (90.57%) and lowest in 2020 (-193.52%).
How does Ever Supreme Bio Technology Co., Ltd's operating margin compare with similar companies?
Ever Supreme Bio Technology Co., Ltd's operating margin (44.16%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.